Company news
Crossject Sa (EURONEXT:ALCJ) news
Crossject Sa news releases on 6ix. Latest, Sep 25, 2026: CROSSJECT structure sa gouvernance pour la phase de déploiement industriel et commercial
Press releases & updates
CROSSJECT structure sa gouvernance pour la phase de déploiement industriel et commercial
September 24, 2026
CROSSJECT strengthens its governance for the industrial and commercial deployment phase
September 24, 2026
CROSSJECT Reports Its First-Half 2026 Results and Presents a Significantly Strengthened Financial Structure
September 24, 2026
CROSSJECT publie ses résultats du premier semestre 2026 et présente une structure financière profondément renforcée
September 24, 2026
CROSSJECT Reports Its First-Half 2026 Results and Presents a Significantly Strengthened Financial Structure
September 25, 2026
CROSSJECT publie ses résultats du premier semestre 2026 et présente une structure financière profondément renforcée
September 24, 2026
CROSSJECT and BARDA align ZEPIZURE®’s Pediatric development plan with FDA including funding through 2030
September 23, 2026
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
July 20, 2026
CROSSJECT announces the successful completion of an equity financing and warrant issuance for a total immediate gross amount of €15 million
May 22, 2026
CROSSJECT appoints Lionel Seltz as Chief Financial Officer
March 25, 2026
CROSSJECT publishes its 2025 financial results and confirms the strengthening of its operational, industrial and financial trajectory
March 25, 2026
CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group)
February 2, 2026
CROSSJECT completes €5 million financing with Vatel Capital
November 14, 2025
CROSSJECT presents its financial results and key highlights for the first half of 2025
September 24, 2025
CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam)
September 22, 2025
CROSSJECT remains engaged during the summer break
August 4, 2025
CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause
June 24, 2025
CROSSJECT advances on the development of ZEPIZURE Junior, its solution for epilepsy crises in children
June 12, 2025
CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children
June 11, 2025
Launch of a capital increase with preferential subscription rights for nearly 5 million euros
June 4, 2025
Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00
June 3, 2025
CROSSJECT implements new manufacturing module to scale-up the ZENEO® Factory ‘s versatility and capacity in anticipation of full product pipeline deployment
May 27, 2025
CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval
May 20, 2025
CROSSJECT’s ZENEO® needle-free autoinjector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors
May 15, 2025
CROSSJECT provides updates on the EUA filing of ZEPIZURE®
May 7, 2025